{"id":9006,"date":"2026-02-16T13:33:11","date_gmt":"2026-02-16T13:33:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/9006\/"},"modified":"2026-02-16T13:33:11","modified_gmt":"2026-02-16T13:33:11","slug":"is-it-time-to-reassess-roche-holding-swxrog-after-its-strong-multi-year-share-price-run","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/9006\/","title":{"rendered":"Is It Time To Reassess Roche Holding (SWX:ROG) After Its Strong Multi Year Share Price Run?"},"content":{"rendered":"\n

Never miss an important update on your stock portfolio<\/a> and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.<\/p>\n

If you are trying to work out whether Roche Holding is reasonably priced or not, this article walks through what the current valuation actually says about the stock.<\/p>\n

Roche’s share price recently closed at CHF 360.00, with returns of 1.8% over 7 days, 3.2% over 30 days, 10.6% year to date, 26.4% over 1 year and 43.4% over 3 years, plus 40.3% over 5 years, which is likely to have shaped how investors think about its potential and risks.<\/p>\n

Recent news around Roche has continued to focus on its position as a major healthcare company and the market’s interest in how its product portfolio and pipeline could affect long term prospects. This background helps frame why investors are paying close attention to where the current share price sits relative to different measures of fair value.<\/p>\n

On our framework, Roche scores a 5\/6 valuation check result. This suggests the stock screens as undervalued on most of the metrics we test. Next, we look at those methods in more detail before touching on an even richer way to think about valuation at the end of the article.<\/p>\n

Find out why Roche Holding’s 26.4% return over the last year is lagging behind its peers.<\/a><\/p>\n

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting them back to today using a required return. It is essentially asking what those future CHF amounts might be worth in today’s money.<\/p>\n

For Roche Holding, the model used is a 2 Stage Free Cash Flow to Equity approach, based on free cash flow in CHF. The latest twelve month free cash flow is CHF 13.6b. Analysts have provided detailed projections out to 2030, with free cash flow in that year estimated at CHF 22.3b. Simply Wall St has then extrapolated further cash flows beyond the explicit analyst horizon.<\/p>\n

When these projected cash flows are discounted back and aggregated, the resulting intrinsic value from the DCF model is CHF 887.22 per share. Compared with the recent share price of CHF 360.00, the model output implies that Roche is 59.4% undervalued on this basis.<\/p>\n

Result: UNDERVALUED<\/p>\n

Our Discounted Cash Flow (DCF) analysis suggests Roche Holding is undervalued by 59.4%. Track this in your watchlist<\/a> or portfolio<\/a>, or discover 226 more high quality undervalued stocks<\/a>.<\/p>\n

\"ROG<\/a> ROG Discounted Cash Flow as at Feb 2026 <\/p>\n

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Roche Holding.<\/a><\/p>\n

For a profitable company like Roche Holding, the P\/E ratio is a useful shorthand for what investors are willing to pay today for each unit of current earnings. It ties the share price directly to the bottom line, which is what ultimately matters for shareholders over time.<\/p>\n

What counts as a \u201cnormal\u201d or \u201cfair\u201d P\/E depends on how the market views a company\u2019s earnings growth prospects and risks. Higher expected growth or lower perceived risk can justify a higher P\/E, while slower growth or higher uncertainty can point to a lower one.<\/p>\n

Roche\u2019s current P\/E is 22.24x, which is very close to the Pharmaceuticals industry average of 22.24x, and well below the peer group average of 86.80x. Simply Wall St also calculates a proprietary \u201cFair Ratio\u201d of 42.00x for Roche, which is the P\/E level its model suggests based on factors such as earnings growth, industry, profit margins, market cap and risk profile.<\/p>\n

This Fair Ratio aims to be more tailored than a simple peer or industry comparison because it adjusts for Roche\u2019s specific characteristics rather than assuming one size fits all benchmarks. With the current P\/E of 22.24x sitting well below the Fair Ratio of 42.00x, this approach indicates that the shares screen as undervalued on an earnings multiple basis.<\/p>\n

Result: UNDERVALUED<\/p>\n

\"SWX:ROG<\/a> SWX:ROG P\/E Ratio as at Feb 2026 <\/p>\n

P\/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 103 top founder-led companies<\/a>.<\/p>\n

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, which are simple stories you create about Roche Holding that connect your view on its products, pipeline, risks and opportunities to a set of numbers such as future revenue, earnings, margins and a fair value estimate. You can then compare that fair value to today\u2019s price using an easy tool on Simply Wall St\u2019s Community page, where Narratives are refreshed whenever new news or earnings land. For example, one Roche Narrative might point to a fair value around CHF 230 while another points closer to CHF 430. This shows how two investors can look at the same company and reach very different, but clearly quantified, conclusions about what the shares are worth and when they might want to act.<\/p>\n

For Roche Holding, here are previews of two leading Roche Holding narratives:<\/p>\n

\ud83d\udc02 Roche Holding Bull Case<\/p>\n

Fair value in this bull case: CHF 430.01 per share<\/p>\n

Implied discount vs last close of CHF 360.00: 16.3% undervalued based on this narrative<\/p>\n

Revenue growth assumption in this narrative: 6.77%<\/p>\n

Highlights Roche\u2019s large scale across Pharmaceuticals and Diagnostics, along with recent full year 2025 results that include steady reported revenue and profit, plus higher earnings per share helped by prior year impairments.<\/p>\n

Focuses on the product pipeline, including CT 388 in obesity, giredestrant for breast cancer and fenebrutinib in multiple sclerosis, along with several Phase III readouts in 2026 and no near term patent cliff.<\/p>\n

Uses free cash flow, growth and P\/E scenarios to arrive at a fair value around CHF 430 per share, framed as higher than the current share price in that narrative.<\/p>\n

\ud83d\udc3b Roche Holding Bear Case<\/p>\n

Fair value in this bear case: CHF 323.28 per share<\/p>\n

Implied premium vs last close of CHF 360.00: 11.4% overvalued based on this narrative<\/p>\n

Revenue growth assumption in this narrative: 1.53%<\/p>\n

Emphasises that analyst expectations for earnings and margin expansion rest on continued execution in diagnostics, oncology and neurology, supported by automation and AI projects and expansion in emerging markets.<\/p>\n

Flags risks around pricing pressure in China and other key regions, patent expiries on several biologics, late stage trial setbacks and reimbursement changes that could affect future earnings.<\/p>\n

Summarises the analyst consensus fair value at CHF 323.28, with targets spread between CHF 230.00 and CHF 438.00, and encourages investors to test those inputs against their own assumptions.<\/p>\n

Do you think there’s more to the story for Roche Holding? Head over to our Community to see what others are saying!<\/a><\/p>\n

\"SWX:ROG<\/a> SWX:ROG 1-Year Stock Price Chart <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include ROG.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…\n","protected":false},"author":2,"featured_media":9007,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[3632,962,1103,1104,1105,134,994,7154,842],"class_list":{"0":"post-9006","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-cash-flow","9":"tag-chf","10":"tag-dcf","11":"tag-fair-value","12":"tag-free-cash-flow","13":"tag-roche","14":"tag-roche-holding","15":"tag-roche-narrative","16":"tag-share-price"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/9006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=9006"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/9006\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/9007"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=9006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=9006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=9006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}